Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women

Pharmacogenetics and Genomics

Volumn 15, Issue 10, 2005, Pages 749-752

  Sillanpää, Pia ^a   Kataja, Vesa ^b   Eskelinen, Matti ^b   Kosma, Veli Matti ^b,c   Uusitupa, Matti ^c   Vainio, Harri ^a   Mitrunen, Katja ^a   Hirvonen, Ari ^a  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Breast cancer; Individual susceptibility; SULT1A1

Indexed keywords

SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BIOTRANSFORMATION; BREAST CANCER; CANCER RISK; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PARITY; POPULATION RESEARCH; PREMENOPAUSE; PRIORITY JOURNAL;

NICOTIANA TABACUM;

EID: 25144525525     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000172240.34923.46     Document Type: Article

References (18)

1. Glatt H, Meinl W. Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedeberg's Arch Pharmacol 2004; 369:55-68.
2. Falany CN. Enzymology of human cytosolic sulfotransferases. FASEB J 1997; 11:206-216.
3. Engelke CE, Meinl W, Boeing H, Glatt H. Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2. Pharmacogenetics 2000; 10:163-169.
4. Carlini EJ, Raftogianis RB, Wood TC, Jin F, Zheng W, Rebbeck TR, et al. Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 2001; 11:57-68.
5. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 1997; 239:298-304.
6. Hildebrandt MA, Salavaggione OE, Martin YN, Flynn HC, Jalal S, Wieben ED, et al. Human SULT1A3 pharmacogenetics: gene duplication and functional genomic studies. Biochem Biophys Res Commun 2004; 321:870-878.
7. Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, et al. Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 2000; 60:6859-6863.
8. Zheng W, Xie D, Cerhan JR, Sellers TA, Wen W, Folsom AR. Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10:89-94.
9. Saintot M, Malaveille C, Hautefeuille A, Gerber M. Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk. Int J Cancer 2003; 107:652-657.
10. Tang D, Rundle A, Mooney L, Cho S, Schnabel F, Estabrook A, et al. Sulfotransferase 1A1 (SULT1A1) polymorphism, PAH-DNA adduct levels in breast tissue and breast cancer risk in a case-control study. Breast Cancer Res Treat 2003; 78:217-222.
11. Sparks R, Ulrich CM, Bigler J, Tworoger SS, Yasui Y, Rajan KB, et al. UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 2004; 6:R488-R498.
12. Männistö S, Pietinen P, Pyy M, Palmgren J, Eskelinen M, Uusitupa M. Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status. Int J Cancer 1996; 68:8-13.
13. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, et al. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9:1343-1348.
14. Peltonen L, Jalanko A, Varilo T. Molecular genetics of the Finnish disease heritage. Hum Mol Genet 1999; 8:1913-1923.
15. 125I- labelled ligand. Acta Endocrinol (Copenh) 1983; 103:282-288.
16. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368:237-239.
17. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998; 58:2269-2277.
18. Spink BC, Katz BH, Hussain MM, Pang S, Connor SP, Aldous KM, et al. SULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells. Carcinogenesis 2000; 21:1947-1957.